Fatty acid oxidation drives acetyl-CoA-dependent H3K9ac reprogramming to promote adaptive resistance to BRAFV600E inhibition in thyroid cancer

Lyu Z, Zhang Y, Sheng C, Huang Y, Zhang Q, Chen K. Global burden of thyroid cancer in 2022: Incidence and mortality estimates from GLOBOCAN. Chin Med J. 2024;137:2567–76.

Google Scholar 

Janjua N, Wreesmann VB. Aggressive differentiated thyroid cancer. Eur J Surg Oncol. 2018;44:367–77.

Google Scholar 

Maniakas A, Zafereo M, Cabanillas ME. Anaplastic thyroid cancer: new horizons and challenges. Endocrinol Metab Clin North Am. 2022;51:391–401.

Google Scholar 

Scheffel RS, Dora JM, Maia AL. BRAF mutations in thyroid cancer. Curr Opin Oncol. 2022;34:9–18.

Google Scholar 

Kim S, Carvajal R, Kim M, Yang HW. Kinetics of RTK activation determine ERK reactivation and resistance to dual BRAF/MEK inhibition in melanoma. Cell Rep. 2023;42:112570.

Google Scholar 

Shimizu Y, Maruyama K, Suzuki M, Kawachi H, Low SK, Oh-Hara T, et al. Acquired resistance to BRAF inhibitors is mediated by BRAF splicing variants in BRAF V600E mutation-positive colorectal neuroendocrine carcinoma. Cancer Lett. 2022;543:215799.

Google Scholar 

Proietti I, Skroza N, Bernardini N, Tolino E, Balduzzi V, Marchesiello A, et al. Mechanisms of acquired Braf inhibitor resistance in melanoma: a systematic review. Cancers. 2020;12:2801.

Parmenter TJ, Kleinschmidt M, Kinross KM, Bond ST, Li J, Kaadige MR, et al. Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discov. 2014;4:423–33.

Google Scholar 

Wang W, Kang H, Zhao Y, Min I, Wyrwas B, Moore M, et al. Targeting autophagy sensitizes BRAF-mutant thyroid cancer to vemurafenib. J Clin Endocrinol Metab. 2017;102:634–43.

Google Scholar 

Chen S, Su X, Jiang X, Zhang T, Min I, Ding Y, et al. VCAM-1 upregulation contributes to insensitivity of vemurafenib in BRAF-mutant thyroid cancer. Transl Oncol. 2020;13:441–51.

Google Scholar 

Cao Y. Adipocyte and lipid metabolism in cancer drug resistance. J Clin Investig. 2019;129:3006–17.

Google Scholar 

Yuan J, Chen Z, Zhang J, Chen X, Chen S, Wang X, et al. Preoperative serum lipids as novel predictors of survival in 3575 patients with papillary thyroid cancer. J Clin Endocrinol Metab. 2025;110:668–76.

Google Scholar 

Ma Y, Temkin SM, Hawkridge AM, Guo C, Wang W, Wang XY, et al. Fatty acid oxidation: an emerging facet of metabolic transformation in cancer. Cancer Lett. 2018;435:92–100.

Google Scholar 

Xiao L, Ma X, Ye L, Su P, Xiong W, Bi E, et al. IL-9/STAT3/fatty acid oxidation-mediated lipid peroxidation contributes to Tc9 cell longevity and enhanced antitumor activity. J Clin Investig. 2022;132:e153247.

Li J, Xia Q, Di C, Li C, Si H, Zhou B, et al. Tumor cell-intrinsic CD96 mediates chemoresistance and cancer stemness by regulating mitochondrial fatty acid beta-oxidation. Adv Sci. 2023;10:e2202956.

Google Scholar 

Sun L, Zhang H, Gao P. Metabolic reprogramming and epigenetic modifications on the path to cancer. Protein Cell. 2022;13:877–919.

Google Scholar 

Wang X, Ying T, Yuan J, Wang Y, Su X, Chen S, et al. BRAFV600E restructures cellular lactylation to promote anaplastic thyroid cancer proliferation. Endocr Relat Cancer 2023;30:e220344.

He W, Li Q, Li X. Acetyl-CoA regulates lipid metabolism and histone acetylation modification in cancer. Biochim Biophys Acta Rev Cancer. 2023;1878:188837.

Google Scholar 

Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, et al. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann Oncol. 2022;33:406–15.

Google Scholar 

Aloia A, Mullhaupt D, Chabbert CD, Eberhart T, Fluckiger-Mangual S, Vukolic A, et al. A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated melanoma to MAPK inhibitors. Clin Cancer Res. 2019;25:6852–67.

Google Scholar 

Liao J, Xie X, Wang N, Wang Y, Zhao J, Chen F, et al. Formononetin promotes fatty acid beta-oxidation to treat non-alcoholic steatohepatitis through SIRT1/PGC-1alpha/PPARalpha pathway. Phytomedicine. 2024;124:155285.

Google Scholar 

She C, Wu C, Guo W, Xie Y, Li S, Liu W, et al. Combination of RUNX1 inhibitor and gemcitabine mitigates chemo-resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2alpha-axis-mediated endoplasmic reticulum stress. J Exp Clin Cancer Res. 2023;42:238.

Google Scholar 

Smith RL, Soeters MR, Wust RCI, Houtkooper RH. Metabolic flexibility as an adaptation to energy resources and requirements in health and disease. Endocr Rev. 2018;39:489–517.

Google Scholar 

Lin J, Rao D, Zhang M, Gao Q. Metabolic reprogramming in the tumor microenvironment of liver cancer. J Hematol Oncol. 2024;17:6.

Google Scholar 

Shen S, Vagner S, Robert C. Persistent cancer cells: the deadly survivors. Cell. 2020;183:860–74.

Google Scholar 

Sultana A, Reilly J, Fenton M. Thioridazine for schizophrenia. Cochrane Database Syst Rev. 2000:3:CD001944.

Aslostovar L, Boyd AL, Almakadi M, Collins TJ, Leong DP, Tirona RG, et al. A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia. Blood Adv. 2018;2:1935–45.

Google Scholar 

Mah CY, Nguyen ADT, Niijima T, Helm M, Dehairs J, Ryan FJ, et al. Peroxisomal beta-oxidation enzyme, DECR2, regulates lipid metabolism and promotes treatment resistance in advanced prostate cancer. Br J Cancer. 2024;130:741–54.

Google Scholar 

Shen S, Faouzi S, Souquere S, Roy S, Routier E, Libenciuc C, et al. Melanoma persister cells are tolerant to BRAF/MEK inhibitors via ACOX1-mediated fatty acid oxidation. Cell Rep. 2020;33:108421.

Google Scholar 

Tan Y, Li J, Zhao G, Huang KC, Cárdenas H, Wang Y, et al. Metabolic reprogramming from glycolysis to fatty acid uptake and beta-oxidation in platinum-resistant cancer cells. Nat Commun. 2022;13:4554.

Google Scholar 

Yu J, Du Y, Liu C, Xie Y, Yuan M, Shan M, et al. Low GPR81 in ER(+) breast cancer cells drives tamoxifen resistance through inducing PPARalpha-mediated fatty acid oxidation. Life Sci. 2024;350:122763.

Google Scholar 

Liu CL, Yang PS, Wang TY, Huang SY, Kuo YH, Cheng SP. PGC1alpha downregulation and glycolytic phenotype in thyroid cancer. J Cancer. 2019;10:3819–29.

Google Scholar 

Gao Y, Yang F, Yang XA, Zhang L, Yu H, Cheng X, et al. Mitochondrial metabolism is inhibited by the HIF1alpha-MYC-PGC-1beta axis in BRAF V600E thyroid cancer. FEBS J. 2019;286:1420–36.

Google Scholar 

Abu Shelbayeh O, Arroum T, Morris S, Busch KB. PGC-1alpha is a master regulator of mitochondrial lifecycle and ROS stress response. Antioxidants. 2023;12:1075.

Alvarez-Guardia D, Palomer X, Coll T, Davidson MM, Chan TO, Feldman AM, et al. The p65 subunit of NF-kappaB binds to PGC-1alpha, linking inflammation and metabolic disturbances in cardiac cells. Cardiovasc Res. 2010;87:449–58.

Google Scholar 

Jimenez-Mora E, Gallego B, Diaz-Gago S, Lasa M, Baquero P, Chiloeches A. (V600E)BRAF inhibition induces cytoprotective autophagy through AMPK in thyroid cancer cells. Int J Mol Sci 2021;22:6033.

Du J, Yi X, Guo S, Wang H, Shi Q, Zhang J, et al. SIRT7 promotes mitochondrial biogenesis to render the adaptive resistance to MAPK inhibition in melanoma. Biochem Biophys Res Commun. 2024;722:150161.

Google Scholar 

Liu J, Suresh Kumar KG, Yu D, Molton SA, McMahon M, Herlyn M, et al. Oncogenic BRAF regulates beta-Trcp expression and NF-kappaB activity in human melanoma cells. Oncogene. 2007;26:1954–8.

Google Scholar 

Haq R, Shoag J, Andreu-Perez P, Yokoyama S, Edelman H, Rowe GC, et al. Oncogenic BRAF regulates oxidative metabolism via PGC1alpha and MITF. Cancer Cell. 2013;23:302–15.

Google Scholar 

Lopez-Marquez A, Carrasco-Lopez C, Fernandez-Mendez C, Santisteban P. Unraveling the complex interplay between transcription factors and signaling molecules in thyroid differentiation and function, from embryos to adults. Front Endocrinol. 2021;12:654569.

Google Scholar 

Dumesic PA, Wilensky SE, Bose S, Van Vranken JG, Gygi SP, Spiegelman BM. RBM43 controls PGC1alpha translation and a PGC1alpha-STING signaling axis. Cell Metab. 2025;37:742–57.e748.

Google Scholar 

Smith LK, Parmenter T, Kleinschmidt M, Kusnadi EP, Kang J, Martin CA, et al. Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAF(V600) melanoma. Nat Commun. 2022;13:1100.

Google Scholar 

Guertin DA, Wellen KE. Acetyl-CoA metabolism in cancer. Nat Rev Cancer. 2023;23:156–72.

Google Scholar 

Li YJ, Fahrmann JF, Aftabizadeh M, Zhao Q, Tripathi SC, Zhang C, et al. Fatty acid oxidation protects cancer cells from apoptosis by increasing mitochondrial membrane lipids. Cell Rep. 2022;39:110870.

Google Scholar 

Shvedunova M, Akhtar A. Modulation of cellular processes by histone and non-histone protein acetylation. Nat Rev Mol Cell Biol. 2022;23:329–49.

Google Scholar 

Gayatri MB, Kancha RK, Behera A, Patchva D, Velugonda N, Gundeti S, et al. AMPK-induced novel phosphorylation of RUNX1 inhibits STAT3 activation and overcomes imatinib resistance in chronic myelogenous leukemia (CML) subjects. Cell Death Discov. 2023;9:401.

Google Scholar 

Ma S, Xu Y, Qin X, Tao M, Gu X, Shen L, et al. RUNX1, FUS, and ELAVL1-induced circPTPN22 promote gastric cancer cell proliferation, migration, and invasion through miR-6788-5p/PAK1 axis-mediated autophagy. Cell Mol Biol Lett. 2024;29:95.

Google Scholar 

Xiao L, Peng Z, Zhu A, Xue R, Lu R, Mi J, et al. Inhibition of RUNX1 promotes cisplatin-induced apoptosis in ovarian cancer cells. Biochem Pharmacol. 2020;180:114116.

Google Scholar 

Cui X, Huo D, Wang Q, Wang Y, Liu X, Zhao K, et al. RUNX1/NPM1/H3K4me3 complex contributes to extracellular matrix remodeling via enhancing FOSL2 transcriptional activation in glioblastoma. Cell Death Dis. 2024;15:98.

Google Scholar 

Browne G, Taipaleenmaki H, Bishop NM, Madasu SC, Shaw LM, van Wijnen AJ, et al. Runx1 is associated with breast cancer progression in MMTV-PyMT transgenic mice, and its depletion in vitro inhibits migration and invasion. J Cell Physiol. 2015;230:2522–32.

Google Scholar 

Li J, Yin Y, Huang H, Li M, Li H, Zhang M, et al. RUNX1 methylation as a cancer biomarker in differentiating papillary thyroid cancer from benign thyroid nodules. Epigenomics. 2023;15:1257–72.

Google Scholar 

Kang S, Dong SM, Kim BR, Park MS, Trink B, Byun HJ, et al. Thioridazine induces apoptosis by targeting the PI3K/Akt/mTOR pathway in cervical and endometrial cancer cells. Apoptosis. 2012;17:989–97.

Google Scholar